Sarepta Announces CEO Departure But Remains On Track For DMD Drug Approval
April 01, 2015 at 13:27 PM EDT
CEO of Sarepta resigned on Tuesday but company states it remains on track for Eteplirsen approval, names Kaye interim CEO. Stock up 6%.